We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Latest News

News

GE and Lilly Collaborates to Co-Develop Molecular In-Vitro Diagnostics for Cancer Treatments

The collaboration is focused on developing diagnostic tools to predict patients’ response to targeted therapies.
News

New Nordic EMBL Partnership for Molecular Medicine

EMBL has partnered with Universities of Finland, Oslo and Umea to explore molecularly and genetically based treatments.
News

Cellumen Establishes Collaboration in Breast Cancer Patient Stratification

The goal of collaboration is to create a breast cancer patient profile test to improve diagnosis and treatment for individualized medicine.
News

Agendia Joins the Personalized Medicine Coalition

The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling.
News

DxS K-RAS Mutation Detection Kit Used To Assess Tumour Mutation Status Prior to Treatment with Amgen’s Vectibix™

Amgen has selected Kit to analyse patient samples from the pivotal“408” study examining Vectibix versus best supportive care in patients with metastatic colorectal cancer.
News

Molecular Sensing to Commercialize New Biosensor Technology Exclusively Licensed from Vanderbilt University

MSI plans to produce biosensor products for research, diagnostic, biodefense and pharmacogenomic applications.
News

Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment

Software to save years in research that aligns patients and treatments.
News

Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex

New agreement to drive the development of OGeS’ own pipeline of antibodies in cancer.
News

FDA Clears Genetic Lab Test for Warfarin Sensitivity

Research has shown that some of the unexpected response to warfarin depends on variants of two genes, CYP2C9 and VKORC1.
News

bioMerieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for new Breast Cancer Treatment

bioMerieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen.
Advertisement